id: metabolic_syndrome_prevalence_to_NEW:metabolic_dysfunction_associated_fatty_liver_disease_mafld
name: Metabolic Syndrome Prevalence â†’ Metabolic Dysfunction-Associated Fatty Liver
  Disease (MAFLD)
from_node:
  node_id: metabolic_syndrome_prevalence
  node_name: Metabolic Syndrome Prevalence
to_node:
  node_id: NEW:metabolic_dysfunction_associated_fatty_liver_disease_mafld
  node_name: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Metabolic syndrome components (obesity, insulin resistance, dyslipidemia,
  hypertension) create systemic metabolic dysfunction'
- 'Step 2: Insulin resistance promotes de novo lipogenesis in hepatocytes and reduces
  fatty acid oxidation, leading to hepatic fat accumulation'
- 'Step 3: Adipose tissue dysfunction releases excess free fatty acids and pro-inflammatory
  cytokines that traffic to the liver'
- 'Step 4: Hepatic steatosis develops when lipid accumulation exceeds the liver''s
  metabolic capacity, meeting MAFLD diagnostic criteria (steatosis plus metabolic
  dysfunction markers)'
- 'Step 5: MAFLD by definition requires metabolic dysfunction (overweight/obesity,
  type 2 diabetes, or metabolic dysregulation), directly linking metabolic syndrome
  components to disease diagnosis'
evidence:
  quality_rating: A
  n_studies: 22
  primary_citation: 'Harry Crane et al. 2024. Global prevalence of metabolic dysfunction-associated
    fatty liver disease-related hepatocellular carcinoma: A systematic review and
    meta-analysis. Clinical and Molecular Hepatology.'
  supporting_citations: []
description: Metabolic syndrome prevalence directly contributes to MAFLD through shared
  pathophysiological mechanisms. MAFLD diagnostic criteria explicitly require metabolic
  dysfunction markers (overweight/obesity with ethnicity-specific BMI thresholds,
  type 2 diabetes, or evidence of metabolic dysregulation) in addition to hepatic
  steatosis. This meta-analysis found that 48.7% of hepatocellular carcinoma patients
  had MAFLD, with metabolic dysfunction serving as both a defining criterion and causal
  pathway. The high prevalence of MAFLD as a co-factor in other liver diseases (40-64%)
  demonstrates how metabolic syndrome amplifies liver disease progression across multiple
  etiologies.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 48.7
    type: prevalence_percentage
    ci_lower: 34.5
    ci_upper: 63.0
  p_value: null
  sample_size: 56565
moderators:
- name: concurrent_liver_disease
  direction: strengthens
  strength: strong
  description: 'MAFLD prevalence was higher in mixed-aetiology cases: 40.0% in hepatitis
    B, 54.1% in hepatitis C, and 64.3% in alcohol-related liver disease cohorts'
- name: ethnicity
  direction: strengthens
  strength: moderate
  description: Ethnicity-specific BMI cut-offs affect MAFLD diagnosis thresholds,
    suggesting varying susceptibility across populations
